Biomedical
Proteasome Inhibitors & Targeted Protein Degradation
Redirecting adaptive autophagy to enhance cancer therapy
Current proteasome inhibitor therapies for multiple myeloma and mantle
cell lymphoma induce an adaptive autophagy response in cancer cells,
which decreases their efficacy and limits their use in solid tumors.
Researchers at Virginia Commonwealth University have developed a novel
therapeutic strategy that harnesses proteasome inhibitor-induced
autophagy to selectively degrade resistance-associated proteins. Using
Autophagy-Targeting Chimeras (AUTACs), this approach enhances cancer cell
death and overcomes resistance, significantly improving the effectiveness of
proteasome inhibitor-based treatments.